Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation.

@article{Sato2015PulmonaryAI,
  title={Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation.},
  author={Seijiro Sato and Noriko Motoi and Miyako Hiramatsu and Eisaku Miyauchi and Hiroshi Ono and Yuichi Saito and Hiroko Nagano and Hironori Ninomiya and Yuichi Ishikawa and Hirofumi Uehara and Mingyon Mun and Yukinori Sakao and Sakae Okumura and Masanori Tsuchida},
  journal={The American journal of surgical pathology},
  year={2015},
  volume={39 7},
  pages={912-21}
}
Lung adenocarcinomas in situ (AISs) often occur in individuals who have never smoked, although smoking is one of the main causes of lung cancer. To characterize AIS and, in particular, determine how AIS might be related to smoking, we collected a large number of AIS cases and examined clinicopathologic features, EGFR and KRAS mutation status, and activation status of receptor tyrosine kinase downstream signal pathways, including pAkt, pERK, and pStat3, using immunohistochemistry. We identified… CONTINUE READING